Catalyst Biosciences Inc Stock
Price
Target price
-
-
-
-
-
?23.10
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Catalyst Biosciences Inc Stock
Catalyst Biosciences Inc is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
Based on the current price of 0.52 € the target price of 23 € shows a potential of 4327.33% for Catalyst Biosciences Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Catalyst Biosciences Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Catalyst Biosciences Inc in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Catalyst Biosciences Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Catalyst Biosciences Inc | - | - | - | - | - | - | - |
| Rockwell Medical Inc. | 0.950% | 17.485% | 35.719% | -54.230% | 41.537% | -44.971% | -92.496% |
| Pacira Pharmaceuticals | -1.690% | 5.455% | -19.444% | -20.183% | -19.444% | -48.824% | -69.204% |
| Twist Bioscience Corp | -3.700% | 1.764% | 26.532% | -29.437% | 30.485% | 41.815% | -76.403% |
Comments
Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
Show more
Ratings data for CBIO provided by MarketBeat
Crescent Biopharma (NASDAQ:CBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Show more
Ratings data for CBIO provided by MarketBeat
Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $26.00 price target on the stock.
Show more
Ratings data for CBIO provided by MarketBeat
